Late Stage Biopharma RayzeBio Files For U.S. IPO (RYZB)

There’s always something waiting to be discovered


A Quick Take On RayzeBio, Inc.

RayzeBio, Inc. (RYZB) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.

The firm is a clinical-stage biopharma developing radiopharmaceutical treatments

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *